Table 4.
Cox regression models to evaluate the risk of disease activity based on CHI3L1 CSF concentrations
| HR | 95% CIs | p | |
|---|---|---|---|
| Time to first relapse | |||
| CHI3L1 low | 1.0 | Ref | |
| CHI3L1 intermediate | 1.96 | 0.73–5.26 | 0.180 |
| CHI3L1 high | 4.57 | 1.73–12.10 | 0.002 |
| Time to first MRI activity | |||
| CHI3L1 low | 1.0 | Ref | |
| CHI3L1 intermediate | 1.02 | 0.51–2.03 | 0.957 |
| CHI3L1 high | 2.46 | 1.26–4.80 | 0.008 |
| Time to disability progression | |||
| CHI3L1 low | 1.0 | Ref | |
| CHI3L1 intermediate | 1.99 | 0.18–22.0 | 0.574 |
| CHI3L1 high | 9.08 | 1.03–80.3 | 0.047 |
| Time to first disease activity | |||
| CHI3L1 low | 1.0 | Ref | |
| CHI3L1 intermediate | 1.25 | 0.66–2.38 | 0.500 |
| CHI3L1 high | 2.90 | 1.52–5.52 | 0.001 |
HR, hazard ratio; 95% CIs, 95% confidence intervals. In bold are reported significant differences at a two-sided α level < 0.05. CHI3L1, chitinase 3-like1; CSF, cerebrospinal fluid.